Cargando…
Risk management of biosimilars in oncology: each medicine is a work in progress
Drug licensing and drug safety monitoring for standard chemical entities have been established and are routinely used. These have resulted in a solid foundation of knowledge from which confident therapeutic decisions can be made. For many chemical entities, this advanced level of experience is also...
Autores principales: | Vulto, Arnold G., Crow, Stacy A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291842/ https://www.ncbi.nlm.nih.gov/pubmed/22274817 http://dx.doi.org/10.1007/s11523-011-0188-3 |
Ejemplares similares
-
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019) -
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
por: Vandenplas, Yannick, et al.
Publicado: (2021) -
Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019) -
The process defines the product: what really matters in biosimilar design and production?
por: Vulto, Arnold G., et al.
Publicado: (2017) -
Interchangeability of Biosimilars: Overcoming the Final Hurdles
por: Barbier, Liese, et al.
Publicado: (2021)